GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD
NCT05643638 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect78/100
StatusTERMINATED
PhasePHASE2
Lead sponsorCynata Therapeutics Limited
Last update2026-10-22
Public-record facts
| Intervention | CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs) (BIOLOGICAL), Placebo (BIOLOGICAL), Corticosteroids (DRUG) |
|---|---|
| Condition | Graft Versus Host Disease, Acute |
| Enrollment | 65 |
| Why stopped | Cynata Therapeutics has taken the decision to discontinue the study following the Primary Evaluation period analysis. The results did not demonstrate the anticipated clinical benefit of CYP-001 in combination with corticosteroids in HR-aGVHD. |
| Results posted | No / not indicated |
Why Beacon surfaced it
- The record is terminated and was updated 2026-10-22.
- It is an interventional PHASE2 study with a named biological/biological/drug intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT05643638. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.